title: Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.
abstract: Five patients with active disseminated vitiligo were given 1g of a chimeric (murine/human) monoclonal antibody to CD20 in a single intravenous infusion and followed-up for 6 months. Three of the patients showed an overt clinical and histological improvement of the disease, one presented slight improvement and the remaining patient showed no changes. Improvement was neither associated with changes in laboratory parameters nor to a specific human leucocyte antigen D-related (HLA-DR) phenotype. We believe that these preliminary results are encouraging, and further clinical trials should be undertaken. An important aim should be the finding of a marker with a good response to this therapeutic approach.
authors.affiliation: Laboratorios Clínicos de Puebla, Puebla, Mexico; Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Ruiz-Argüelles
authors.forename: M
authors.initials: M
authors.lastname: García-Carrasco
authors.forename: G
authors.initials: G
authors.lastname: Jimenez-Brito
authors.forename: S
authors.initials: S
authors.lastname: Sánchez-Sosa
authors.forename: B
authors.initials: B
authors.lastname: Pérez-Romano
authors.forename: J
authors.initials: J
authors.lastname: Garcés-Eisele
authors.forename: C
authors.initials: C
authors.lastname: Camacho-Alarcón
authors.forename: V
authors.initials: V
authors.lastname: Reyes-Núñez
authors.forename: M
authors.initials: M
authors.lastname: Sandoval-Cruz
authors.forename: C
authors.initials: C
authors.lastname: Mendoza-Pinto
authors.forename: A
authors.initials: A
authors.lastname: López-Colombo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D054316:Biomarkers, Pharmacological / Q000097:blood; D018450:Disease Progression; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D051379:Mice; D010865:Pilot Projects; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D058408:Th1-Th2 Balance; D016896:Treatment Outcome; D014820:Vitiligo / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D054316:Biomarkers, Pharmacological; D006684:HLA-DR Antigens; D011993:Recombinant Fusion Proteins
keywords: MabThera®; Rituxan®; anti-CD20; rituximab; vitiligo